Company intelligence / Profile preview

Synoste

Espoo, Uusimaa, Finlandinnokasmedical.fi ↗

Ownership: Private
Employees: ~12
Development stage: Clinical

Overview

Synoste developed a fully implantable, smart-materials-based device for lower limb lengthening ("Synoste Nitinail"), offering a less painful and more precisely controllable alternative to traditional external fixation. The technology enables safer treatment with fewer complications and faster recovery. The company achieved CE approval for its lead product prior to acquisition.

Therapeutic areas: OtherRare Diseases
Modalities: DeviceSmart materials-based deviceImplantable medical device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

NitiNail

Clinical

Indications: Bone deformities, Limb length discrepancy

Partnerships

High-Tech Gründerfonds (investor/partner)Evonik Venture Capital (investor/partner)

Beyond the preview

Go deeper on Synoste.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synoste.

Explore the full profile